ライフサイエンスコーパス: IOP

1 IOP changed by -1.2 +/- 5.8 mm Hg (P = .18) in the Repos

2 IOP heritability has been estimated to up to 67%, and to

3 IOP increase was seen in all 3 patients, but could be tr

4 IOP is controlled by the balance between aqueous humor s

5 IOP was measured in the upright position with a Goldmann

6 IOP was measured using a Perkins tonometer in the supine

7 IOP was reduced by 24.4% at 3 years post-surgery, which

8 estimated to up to 67%, and to date only 11 IOP loci have been reported, accounting for 1.5% of IOP

9 ) </= 21 mm Hg and IOP reduction of 20%; (2) IOP </= 18 mm Hg and IOP reduction of 25%; and (3) IOP <

10 75.4% (46/61; observed data) reported >/=20% IOP lowering from baseline on the same or fewer medicati

11 ance outcomes: patients (%) achieving >/=20% IOP reduction from baseline on the same or fewer medicat

12 = 18 mm Hg and IOP reduction of 25%; and (3) IOP </=15 mm Hg and IOP reduction of 30%.

13 values, it was found a 20% greater absolute IOP reduction (median [interquartile range] 6 mmHg [4-7]

14 ons, without glaucoma progression/additional IOP-lowering surgery), Snellen-equivalent visual acuity

15 ucing IOP in patients who require additional IOP lowering after a first AGV.

16 ge and RGC loss at an early time point after IOP elevation.

17 applanation tonometry (GAT) was used for all IOP measurements which were taken at the time of listing

18 a, previous ocular surgery, or trauma and an IOP asymmetry greater than 5 mm Hg between eyes were exc

19 ccess was defined by a good technique and an IOP reading within 5 mm Hg of that obtained by a clinici

20 Complete success was defined as an IOP of 21 mm Hg or less without medications, while quali

21 with HIV were 7 times more likely to have an IOP </=10 mm Hg, and patients with a CD4 count </=700 ce

22 s/mm(3) were 13 times more likely to have an IOP </=10 mm Hg.

23 e qualified success was defined as having an IOP of 21 mm Hg or less with medications.

24 This trial showed an IOP decrease after late in-the-bag IOL dislocation surge

25 different methods, and to assess whether an IOP decrease after surgery can be expected.

26 ker use was independently associated with an IOP of 0.45 mm Hg lower (95% CI, -0.65 to -0.25 mm Hg; P

27 al air tamponade of at least 2 hours with an IOP within the physiological range could help to reduce

28 her early and prolonged use of antiviral and IOP-lowering medication may prevent glaucoma.

29 haemorrhages, ocular medication changes, and IOP-lowering surgery.

30 fraction between -6 diopters (D) to 6 D, and IOP of 6 to 21 mmHg.

31 ECM accumulation leads to TM dysfunction and IOP elevation.

32 amined the relationship between GI group and IOP and medications at one year with a linear regression

33 athy (n = 1) in the repositioning group, and IOP increase (n = 9), pupillary block (n = 1), choroidal

34 intraocular pressure (IOP) </= 21 mm Hg and IOP reduction of 20%; (2) IOP </= 18 mm Hg and IOP reduc

35 P reduction of 20%; (2) IOP </= 18 mm Hg and IOP reduction of 25%; and (3) IOP </=15 mm Hg and IOP re

36 eduction of 25%; and (3) IOP </=15 mm Hg and IOP reduction of 30%.

37 ference (TLCPD) was calculated using ICP and IOP together with geometric distances estimated from mag

38 ents and better appreciation of peak IOP and IOP fluctuation.

39 To compare intraocular pressure (IOP) and IOP-lowering treatment requirements in patients with lat

40 Associations between medication and IOP were assessed using linear regression models adjuste

41 s ICP, assessed through lumbar puncture, and IOP measurements when supine, sitting, and in 9 degrees

42 ect impact on aqueous outflow resistance and IOP.

43 ociation between systemic medication use and IOP in a multiethnic Asian population.

44 association between hormone therapy use and IOP in the context of a large randomized trial.

45 , Snellen-equivalent visual acuity (VA), and IOP at last follow-up.

46 The success criterion was defined as IOP </= 12 mm Hg without and with antiglaucoma medicatio

47 outcome measure was SLT success (defined as IOP </= target IOP in both eyes) at 12 months.

48 On average, IOP by the rebound tonometer was 2.66 mm Hg lower than G

49 Baseline IOP was obtained on 2 different days after washout.

50 After accounting for differences in baseline IOP, laser suture lysis was negatively correlated with l

51 er-protocol population with maximum baseline IOP < 25 mm Hg in both studies (ROCKET-2, primary outcom

52 er, had significantly lower CCT and baseline IOPs, and were more likely to have pseudoexfoliation, di

53 espite significantly lower mean and baseline IOPs.

54 The baseline IOPs were 20.4 +/- 6.0 mmHg and 21.2 +/- 6.1 (mean +/- s

55 g or reduced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss

56 ly significant difference (P < 0.05) between IOP before Nd: YAG laser capsulotomy (16 mmHg +/- 3 mmHg

57 es that assessment of the difference between IOP and ICP in upright position may offer new understand

58 idence that some genomic regions affect both IOP and the disc parameters.

59 A single administration controlled IOP in the majority of patients for up to 6 months.

60 ocular hypertensive eyes compared to daytime IOPs.

61 P-3 increased outflow facility and decreased IOP, and controlled expression using an inducible promot

62 end point was association between discordant IOP measurements and the stage of glaucoma, as assessed

63 s well as the correlation between discordant IOP values and stage of glaucoma.

64 Mean and percent diurnal IOP change from baseline were significantly greater with

65 Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse event

66 , and increase of >/=10 mmHg from documented IOP recordings (or use of treatment for OHT).

67 Elevated IOP, which can be caused by increased resistance to AH o

68 If an elevated IOP occurred, it was usually already present at the star

69 sistance to aqueous humor drainage, elevated IOP, optic nerve degeneration and blindness.

70 riority clinical trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

71 come measures were the incidence of elevated IOP and glaucoma and risk factors for the development of

72 ce had equivalent and significantly elevated IOP with DEX-Ac treatment every week.

73 criteria, our study confirmed that elevated IOP and secondary glaucoma are major complications in he

74 st in normal animals and respond to elevated IOP through softening of the meshwork to increase outflo

75 ignificant incidence of transiently elevated IOP postoperatively, but had a low incidence of de novo

76 n during follow-up for uveitis were elevated IOP (75%), keratitis (59%), dry eyes (34%), posterior sy

77 as recurrence of encapsulation with elevated IOP (15.9%).

78 The majority of patients with elevated IOP (91%) had this already at the start of the uveitis.

79 t how RGC function was altered with elevated IOP under both photopic and scotopic conditions.

80 opment of glaucoma was the number of endured IOP peaks.

81 Cadaver eye IOP measurements were 3.1+/-2.5 mmHg lower than intracam

82 Rabbit eye IOP was modulated through cannulation in ex vivo study o

83 aHR, 1.87); history of OHT in the other eye: IOP >/=21 mmHg (aHR, 2.68), >/=30 mmHg (aHR, 4.86) and p

84 orrecting for potential confounding factors, IOP and age.

85 One early immune response following IOP elevation is up-regulation of complement C3 in astro

86 ne, sitting, or HDT (P >/= 0.11), except for IOP in HDT (P = 0.04).

87 xamined directly to intracameral IOP and GAT IOP.

88 Goldmann IOP measures significantly lower than true intracameral

89 The Goldmann IOP error is increased an additional 2.8 mmHg lower in t

90 The CLHI demonstrated greater IOP reduction than latanoprost ophthalmic solution on da

91 onal 6 patients could use the device but had IOP readings greater than 5 mm Hg different from those o

92 ould change if the patient maintains his/her IOP at 1 of 7 levels (6, 9, 12, 15, 18, 21, or 24 mmHg)

93 High IOP was the most common reason for failure in both group

94 However, associated high IOP was not resolved by dislocation surgery in many pati

95 uced by the increased strain imposed by high IOP.

96 the risk allele of the variant who had high IOP (ocular hypertension) or glaucoma.

97 either preexisting glaucoma (n = 39) or high IOP (>/=22 mm Hg) with suspected glaucoma (n = 23), of w

98 ler height (-0.02 mum/cm; P < 0.001), higher IOP (-0.03 mum/mmHg; P < 0.001), and regular smoking (-0

99 wer (HR 8.98 [95% CI 1.07-75.41]) and higher IOP (HR 10.63 [95% CI 1.44-78.27]) increased the risk of

100 sulfonylurea use was associated with higher IOP in this study, the associations were modest at best.

101 ICP, IOP, and TLCPD in different body positions.

102 olunteers, there were no differences in ICP, IOP, or TLCPD in supine, sitting, or HDT (P >/= 0.11), e

103 changes to MD over the same time horizon if IOP is increased or decreased by 3, 6, and 9 mmHg from t

104 s were performed to assess factors impacting IOP.

105 An increase in outflow facility (decrease in IOP) is demonstrated in a mouse model.

106 mm(3) contributed to a 2.1 mm Hg decrease in IOP.

107 Difference in IOP was the primary outcome being measured.

108 cochlin-overexpression mediated increase in IOP.

109 action between both proteins are involved in IOP regulation.

110 our results, which show a 24.5% reduction in IOP at 3 years with 12% complication rate, we propose th

111 Target IOP was a 20% or greater reduction in IOP from postwashout baseline.

112 ced a statistically significant reduction in IOP, and eyes undergoing IMCT achieved a lower IOP than

113 Absolute CD4 counts may play a role in IOP fluctuations.

114 V is a viable option in eyes with inadequate IOP levels after a primary AGV.

115 Secondary outcome measures include IOP, glaucoma medical therapy, visual acuity, visual fie

116 Secondary outcome measures included IOP thresholds of 6 to 14 mmHg and 6 to 21 mmHg and same

117 tion surgery in many patients, and increased IOP-lowering treatment in the postoperative course was c

118 variant rs74315329 in relation to increased IOP was 12.5% and 19.4% in the TwinsUK and the RS, respe

119 Intracameral IOP ranged between 5 and 60 mmHg.

120 Intracameral IOP was measured via pressure transducer on fifty-eight

121 were 3.1+/-2.5 mmHg lower than intracameral IOP in the upright position and 5.4+/- 3.1 mmHg in the s

122 was 5.2 +/-1.6 mmHg lower than intracameral IOP in the upright position and 7.9 +/- 2.3 mmHg lower i

123 e not been examined directly to intracameral IOP and GAT IOP.

124 s significantly lower than true intracameral IOP by approximately 3 mmHg in vitro and 5 mmHg in vivo.

125 esh human cadaver globes were Intracamerally IOP adjusted and measured via pressure transducer.

126 A larger IOP reduction can be expected in individuals with a high

127 gher GI group had a 1.69 +/- 0.2 mmHg larger IOP decrease.

128 Pre and post-laser IOP values were compared using paired t-test.

129 Considering unadjusted post-laser IOP values, it was found a 20% greater absolute IOP redu

130 Multiple longitudinal IOP measurements were collected through electronic healt

131 Using longitudinal IOP measurements from electronic health records improves

132 Low IOP after trabeculectomy, reoperation, vision loss, and

133 associations between each covariate and low IOP.

134 tically significant associations between low IOP and time to reoperation (hazard ratio [HR], 0.73; 95

135 geons between 1990 and 2013, 64 eyes had low IOP (1.7%), which were compared with 130 control eyes.

136 7); surgeon was correlated with high vs. low IOP after trabeculectomy (OR, 5.32; 95% CI, 1.53-18.52).

137 ure lysis was negatively correlated with low IOP after trabeculectomy (odds ratio [OR], 0.33; 95% con

138 are factors potentially associated with low IOP after trabeculectomy.

139 Fifteen of the 64 eyes with low IOP had hypotony maculopathy (23.4%).

140 Cases with low IOP included all patients with IOP </=5 mmHg on 3 or mor

141 In patients with low IOP, there was a higher unadjusted incidence of bleb rev

142 Control patients without low IOP after trabeculectomy were randomly selected at a 1:2

143 P, and eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 +/-

144 1.2 vs 1.61 +/- 1.51, P < .0001), had lower IOP in first operated eye (15.2 +/- 3.6 vs 18.2 +/- 7.0,

145 In vivo genome editing results in lower IOP and prevents further glaucomatous damage.

146 ay potentially be at risk of higher or lower IOP, depending on medication class, and this would in tu

147 ollow-up and resulted in significantly lower IOP measurements.

148 c beta-blocker use was associated with lower IOP and systemic ACEI, ARB, statin, and sulfonylurea use

149 The CLHI lowered IOP by 10.5+/-1.4, 11.1+/-4.0, and 10.0+/-2.5 mmHg on da

150 chlin play an important role for maintaining IOP homeostasis.

151 Mean IOP at enrollment was 15.4 +/- 3.6 mm Hg in right eyes a

152 Mean IOP change from baseline was -9.1 mm Hg (95% confidence

153 3 year follow-up showed a mean IOP of 13.41 +/- 2.22 mmHg (range 8-18 mmHg).

154 ne on the same or fewer medications and mean IOP change from baseline at month 12.

155 riance (ANOVA) was performed to compare mean IOP values.

156 of de novo glaucoma surgery, and lower mean IOP on fewer medications than the Ahmed group.

157 Overall mean IOP reduction from baseline through week 16 in study eye

158 usive), de novo glaucoma surgery rates, mean IOP, mean glaucoma medication use, and visual acuity wer

159 fornix-based and limbal-based surgery, mean IOP at 12 months was similar, with ranges of 12.5-15.5 m

160 Analysis of covariance showed that mean IOP reduction with LBN was not only noninferior to timol

161 At 5 years, mean IOP was 15.8 +/- 5.2 mm Hg in the Ahmed group and 13.2 +

162 um-tolerated medical therapy, with medicated IOP >/=20 and </=35 mm Hg and visual field mean deviatio

163 ggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provid

164 Nighttime IOPs were higher in ocular hypertensive eyes compared to

165 Compared with normal IOP, lower (HR 8.98 [95% CI 1.07-75.41]) and higher IOP

166 i have been reported, accounting for 1.5% of IOP variability.

167 new variants, which together explain 3.7% of IOP variation.

168 d a genome-wide association meta-analysis of IOP and optic disc parameters and validated our findings

169 Furthermore, elevation of IOP significantly accelerated the photopic temporal tuni

170 glaucoma disease progression irrespective of IOP control.

171 of the filtering bleb and subsequent loss of IOP control.

172 and this would in turn affect management of IOP control.

173 on-glaucoma patients, had a higher number of IOP peaks during their follow-up for uveitis (P < .001).

174 le also providing a more complete picture of IOP changes over time.

175 blish miR-143/145 as important regulators of IOP, which may have important therapeutic implications i

176 rtem clinical findings including severity of IOP elevation, retinal nerve fiber layer thinning, or el

177 e conduct a genome-wide association study of IOP in 69,756 untreated individuals of European, Latino,

178 30 mmHg (aHR, 4.86) and prior/current use of IOP-lowering drops or surgery in the other eye (aHR, 4.1

179 ed POAG were randomized to prompt washout of IOP-lowering medications followed by SLT, 3-month delay

180 ive, synergistic, or antagonistic effects on IOP was not identified.

181 point, the effect of systemic medication on IOP in eyes with glaucoma is not well elucidated but imp

182 evaluate the effect of this MYOC mutation on IOP using data from large-scale European population pane

183 Pre-operative IOP was 17.75 +/- 2.19 mmHg (range 12-21 mmHg).

184 tomy surgery with respect to bleb failure or IOP control was observed in both types of conjunctival f

185 Overall IOP was 18.0 +/- 6.2 mm Hg before surgery and 15.7 +/- 4

186 comparable to topical bimatoprost in overall IOP reduction through week 16.

187 nd were then instructed to measure their own IOP under observation.

188 o be effective treatment for these patients (IOP < 21 mmHg).

189 measurements and better appreciation of peak IOP and IOP fluctuation.

190 in outcome measure was 6-month postoperative IOP change.

191 Thus, TRPV4 is a potential IOP sensor within the conventional outflow pathway and a

192 Mean preoperative IOP of the study population was 31.5 +/- 11.3 mm Hg on a

193 The mean preoperative IOP was 24.70 +/- 3.90 mm Hg in the IMCT group and 24.60

194 = 23), of whom several required preoperative IOP-lowering treatment.

195 were comparable with respect to preoperative IOP, corneal clarity, corneal diameter, vertical cup-to-

196 went SLT, and 103 (6.2%) who were prescribed IOP-lowering medication.

197 urgery or uncontrolled intraocular pressure (IOP) >22 mm Hg, despite topical/systemic medications.

198 d with 3 criteria: (1) intraocular pressure (IOP) </= 21 mm Hg and IOP reduction of 20%; (2) IOP </=

199 rldwide, with elevated intraocular pressure (IOP) a major risk factor.

200 e risk factors for low intraocular pressure (IOP) after trabeculectomy and to describe long-term outc

201 Intraocular pressure (IOP) and cataract formation were determined as safety en

202 To compare intraocular pressure (IOP) and IOP-lowering treatment requirements in patients

203 Intraocular pressure (IOP) and optic nerve head characteristics are used clini

204 incidence of elevated intraocular pressure (IOP) and secondary glaucoma in herpetic anterior uveitis

205 ser capsulotomy on the intraocular pressure (IOP) and the trabeculectomy bleb integrity, in a small s

206 ual to 0.6 with normal intraocular pressure (IOP) and visual fields.

207 OBSERVATION: Intraocular pressure (IOP) at the end of the surgery, immediately after fillin

208 d(s) mice develop high intraocular pressure (IOP) but are protected from retinal ganglion cell (RGC)

209 ely treat glaucomatous intraocular pressure (IOP) dysregulation.

210 ith TM dysfunction and intraocular pressure (IOP) elevation in glaucoma.

211 Intraocular pressure (IOP) elevation was relatively rapid and significant, and

212 lative to intracameral intraocular pressure (IOP) has not been examined comparatively in both human c

213 y (VC/PVC) in lowering intraocular pressure (IOP) in Normal Tension Glaucoma (NTG) patients.

214 mic medication use and intraocular pressure (IOP) in the general population.

215 ive complications were intraocular pressure (IOP) increase (n = 12), cystoid macular edema (CME; n =

216 Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, a leading caus

217 urate determination of intraocular pressure (IOP) is crucial for the diagnosis and management of glau

218 Intraocular pressure (IOP) is maintained as a result of the balance between pr

219 In the eye, intraocular pressure (IOP) is tightly regulated and its persistent increase le

220 ogression at different intraocular pressure (IOP) levels to aid clinicians with setting personalized

221 The mean intraocular pressure (IOP) measured with Goldmann Applanation Tonometry and DC

222 ed 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater than baseline; ocular ad

223 al failure, defined as intraocular pressure (IOP) more than 21 mmHg or reduced by less than 20% from

224 fined as 2 consecutive intraocular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg wi

225 ry outcome measure was intraocular pressure (IOP) reduction.

226 ished by elevating the intraocular pressure (IOP) via microbead occlusion of ocular fluid outflow in

227 rmotensive rabbits and intraocular pressure (IOP) was monitored for 28 days.

228 ICP and intraocular pressure (IOP) were simultaneously measured in supine, sitting, an

229 s to measure their own intraocular pressure (IOP) would allow more frequent measurements and better a

230 urgical details, final intraocular pressure (IOP), and complications were recorded.

231 orporated preoperative intraocular pressure (IOP), number of medications and visual field status.

232 Elevated intraocular pressure (IOP), which causes optic nerve damage and retinal gangli

233 valuate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sust

234 racterize the 12-month intraocular pressure (IOP)-lowering efficacy of selective laser trabeculoplast

235 To evaluate the intraocular pressure (IOP)-lowering performance and safety of an ab interno ge

236 rate prediction of the intraocular pressure (IOP)-lowering response in the fellow eye when using a mo

237 ous humor drainage and intraocular pressure (IOP).

238 glaucoma by increasing intraocular pressure (IOP).

239 (6) hypotony/increased intraocular pressure (IOP); (7) macula pucker/epiretinal membrane; (8) catarac

240 (NO) is able to lower intraocular pressure (IOP); however, its therapeutic effects on outflow physio

241 Postoperative success (intraocular pressure [IOP] < 22 mm Hg +/- glaucoma medications, without glauco

242 ailure rates (using an intraocular pressure [IOP] target of 6-18 mm Hg inclusive), de novo glaucoma s

243 rneal thickness [CCT], intraocular pressure [IOP], refraction, medications), as well as medical, surg

244 rus (HIV) and reduced intraocular pressures (IOP).

245 and incident OHT with intraocular pressures (IOPs) of >/=21 mmHg, >/=30 mmHg, and increase of >/=10 m

246 could be treated sufficiently with primarily IOP lowering medications and without need for glaucoma s

247 four-hour recording with a CLS that provides IOP-related measurements.

248 145 in mice results in significantly reduced IOP, consistent with an 2-fold increase in outflow faci

249 The gelatin stent reduced IOP and medication use without raising unexpected safety

250 Both treatments reduced IOP from baseline, and no safety issues were identified

251 A second AGV is effective in reducing IOP in patients who require additional IOP lowering afte

252 that varies with age, ethnicity, refraction, IOP, and smoking.

253 How microRNAs (miRs) regulate IOP and glaucoma in vivo is largely unknown.

254 lar meshwork (TM), the tissue that regulates IOP.

255 each operation group, respectively, required IOP-lowering treatment with glaucoma medications added,

256 Success required IOP </=22 mm Hg and 20% reduction without additional gla

257 SLT monotherapy safely provides significant IOP reduction in Afro-Caribbean eyes with POAG.

258 We identify 47 genome-wide significant IOP-associated loci (P < 5 x 10(-8)); of the 40 novel lo

259 Medications associated with significant IOP differences were incorporated into regression models

260 A substantial IOP reduction was seen in subjects with more advanced gl

261 c absorption, based on a lack of substantial IOP effects on the fellow untreated eye, compared to bri

262 Bimatoprost SR provided rapid, sustained IOP lowering.

263 Target IOP was a 20% or greater reduction in IOP from postwasho

264 ts of OAG progression under different target IOP levels.

265 s of the change in MD under different target IOP levels.

266 ctory of OAG progression at different target IOP levels.

267 e was SLT success (defined as IOP </= target IOP in both eyes) at 12 months.

268 sus AGIS participants under different target IOPs (P > 0.05 for all).

269 s determine appropriate, personalized target IOPs for patients with OAG.

270 clinicians with setting personalized target IOPs.

271 .8, 2.1, and 4.1 dB MD under the same target IOPs and time frame.

272 6.7, and 11.2 decibels (dB) MD under target IOPs of 6, 15, and 24 mmHg, respectively, over 5 years.

273 This study confirms that IOP rises may also occur in the paediatric population an

274 Here we report that IOP reduction in rabbits receiving a single brimonidine

275 Overall, these results suggest that IOP alters multiple functions in the retina depending on

276 The IOP was reduced from a preoperative mean of 30.4 (+/- 10

277 58) eyes undergoing cataract surgery and the IOP was modulated manometrically on each patient alterna

278 Independent of the IOP, an air tamponade duration beyond 2 hours reduced th

279 We found that some of the IOP-induced functional changes to OFF RGCs relied on ON

280 The IOPs with the rebound tonometer were similar whether obt

281 3 patients, respectively, discontinued their IOP-lowering medication.

282 therapy (HAART) had any difference in their IOP compared with patients without HIV or with HIV who a

283 tic variation influenced POAG either through IOP or via changes to the optic nerve head; here we pres

284 ation between visual field defect and TLCPD, IOP, or ICP and in any body position (P >/= 0.39).

285 Rescue topical IOP-lowering medication or a single repeat treatment wit

286 showed flat filtering bleb and uncontrolled IOP (34.5 +/- 11 mmHg), under maximum topical treatment,

287 /cilioablative procedure or had uncontrolled IOP on maximum-tolerated medical therapy, with medicated

288 ning blebs, were presented with uncontrolled IOP, in a variable distance of time following the applic

289 netrance of this variant was evaluated using IOP measurements and data on visual field testing/a diag

290 diabetes, hypertension, visual acuity (VA), IOP, number of sutures in the scleral flap, laser suture

291 The primary endpoint was IOP change from baseline.

292 The primary outcome measures were IOP reduction and the success rate at 12 months.

293 Thus, when IOP is experimentally elevated, cells of the Cav-1(-/-)

294 An observational study in which IOP was assessed using Goldmann applanation tonometry an

295 than 10 mm Hg greater than baseline, 2 with IOP higher than 35 mm Hg, and 1 with angle-closure glauc

296 h endophthalmitis (culture negative), 9 with IOP more than 10 mm Hg greater than baseline, 2 with IOP

297 atio (VCDR) and 1 new region associated with IOP.

298 The significant association with IOP is especially interesting and may have relevance for

299 esponses to light offset are diminished with IOP elevation along with a concomitant decrease in recep

300 ases with low IOP included all patients with IOP </=5 mmHg on 3 or more consecutive visits 3 months o